JP2024521122A - エキュベクテディンのための投薬レジメン - Google Patents

エキュベクテディンのための投薬レジメン Download PDF

Info

Publication number
JP2024521122A
JP2024521122A JP2023572000A JP2023572000A JP2024521122A JP 2024521122 A JP2024521122 A JP 2024521122A JP 2023572000 A JP2023572000 A JP 2023572000A JP 2023572000 A JP2023572000 A JP 2023572000A JP 2024521122 A JP2024521122 A JP 2024521122A
Authority
JP
Japan
Prior art keywords
compound
cancer
dose
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521122A5 (https=
Inventor
カルメン・カハット
ピラル・ラルデッリ
クリスティアン・フェルナンデス
アルトゥロ・ソト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of JP2024521122A publication Critical patent/JP2024521122A/ja
Publication of JP2024521122A5 publication Critical patent/JP2024521122A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023572000A 2021-05-19 2022-05-19 エキュベクテディンのための投薬レジメン Pending JP2024521122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382455.0 2021-05-19
EP21382455 2021-05-19
PCT/EP2022/063653 WO2022243482A1 (en) 2021-05-19 2022-05-19 Dosage regimens for ecubectedin

Publications (2)

Publication Number Publication Date
JP2024521122A true JP2024521122A (ja) 2024-05-28
JP2024521122A5 JP2024521122A5 (https=) 2025-05-27

Family

ID=76197383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572000A Pending JP2024521122A (ja) 2021-05-19 2022-05-19 エキュベクテディンのための投薬レジメン

Country Status (11)

Country Link
US (1) US20240277705A1 (https=)
EP (1) EP4340841A1 (https=)
JP (1) JP2024521122A (https=)
KR (1) KR20240009437A (https=)
CN (1) CN117295499A (https=)
AU (1) AU2022277799A1 (https=)
CA (1) CA3218171A1 (https=)
IL (1) IL308389A (https=)
MX (1) MX2023013715A (https=)
TW (1) TW202313039A (https=)
WO (1) WO2022243482A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
TW202547489A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
US20240277705A1 (en) 2024-08-22
CA3218171A1 (en) 2022-11-24
CN117295499A (zh) 2023-12-26
EP4340841A1 (en) 2024-03-27
WO2022243482A1 (en) 2022-11-24
MX2023013715A (es) 2024-03-26
KR20240009437A (ko) 2024-01-22
AU2022277799A1 (en) 2023-12-21
TW202313039A (zh) 2023-04-01
IL308389A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
JP2024521122A (ja) エキュベクテディンのための投薬レジメン
ES2941894T3 (es) Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
JP2010059202A (ja) Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
PT1827437E (pt) Combinação de agentes terapêuticos para o tratamento do cancro
JP2012528079A (ja) 癌を治療するためのインテグリンリガンドの連続投与
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
US20240415834A1 (en) Lurbinectedin and atezolizumab combinations
WO2022101255A1 (en) Lurbinectedin and irinotecan combinations
TW201249435A (en) Antitumoral combination comprising cabazitaxel and cisplatin
US11911374B2 (en) Methods and uses for treating cancer
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
KR20070037498A (ko) 에포틸론 조합물
WO2024105049A1 (en) Lurbinectedin and doxorubicin combination
TW201540296A (zh) 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20240216

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421